medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-9-46-49medsovet-2475Research ArticleДЕМИЕЛИНИЗИРУЮЩИЕ ЗАБОЛЕВАНИЯDEMYELINATING DISEASESАлгоритм лечения больного ремитирующим рассеянным склерозом с субоптимальным ответом на примере клинического случаяThe algorithm of treatment of the patient with relapsing-remitting multiple sclerosis with suboptimal response:the example of a clinical caseПоповаЕ. В.PopovaE. V.БрюховВ. В.BryukhovV. V.

Москва

Moscow

БойкоА. Н.BoykoA. N.КротенковаМ. В.KrotenkovaM. V.

Москва

Moscow

ГБУЗ Городская клиническая больница №24 Департамента здравоохранения г. Москвы; ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияInterregional Department of Multiple Sclerosis at Moscow Clinical Hospital №24; Pirogov Russian National Research Medical UniversityRussian FederationФГБНУ Научный центр неврологииРоссияResearch Center of NeurologyRussian Federation201829052018094649Copyright © Попова Е.В., Брюхов В.В., Бойко А.Н., Кротенкова М.В., 20182018Попова Е.В., Брюхов В.В., Бойко А.Н., Кротенкова М.В.Popova E.V., Bryukhov V.V., Boyko A.N., Krotenkova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2475

В данной статье представлен клинический случай субоптимального ответа на терапию рассеянного склероза и алгоритм ведения с учетом имеющихся критериев эффективности.

This article presents a clinical case of suboptimal response to multiple sclerosis therapy and an algorithm for treatment, taking into account the existing performance criteria.

рассеянный склероздиметилфумаратсубоптимальный ответmultiple sclerosisdimethylfumaratesuboptimal responseReferencesLublin FD et al. Defining the clinical course of multiple sclerosis, The 2013 revisions. Neurology, 2014 Jul 15,). 83(3): 278–286. doi:10.1212/WNL.0000000000000560.Lublin FD et al. Defining the clinical course of multiple sclerosis, The 2013 revisions. Neurology, 2014 Jul 15,). 83(3): 278–286. doi:10.1212/WNL.0000000000000560.Freedman M, Rush C Severe, Highly Active, or Aggressive Multiple Sclerosis. CONTINUUM: Lifelong Learning in Neurology, 2016, 22: 761784. doi: 10.1212/con.0000000000000331.Freedman M, Rush C Severe, Highly Active, or Aggressive Multiple Sclerosis. CONTINUUM: Lifelong Learning in Neurology, 2016, 22: 761784. doi: 10.1212/con.0000000000000331.Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology, 69(2): 292-302. doi:10.1002/ana.22366.Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology, 69(2): 292-302. doi:10.1002/ana.22366.Алифирова В.М., Бойко А.Н., Власов Я.В. [и др.]. Клинические рекомендации по применению препарата диметилфумарат при ремитирующе-рецидивирующем рассеянном склерозе. Журн. неврол и психиатр, 2017, 1: 97-102. doi: 10/17116/jnevro20171171197-102.Alifirova VM, Boyko AN, Vlasov YaV, et al. Clinical guidelines for use of dimethyl fumarate in remitting-relapsing multiple sclerosis. Zhurn. Nevrol i Psikhiatr, 2017, 1: 97-102. doi: 10/17116/jnevro20171171197-102Moharregh-Khiabani D, Linker R, Gold R, Stangel M. Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis. Current Neuropharmacology, 2009, 7(1): 60-64. doi:10.2174/157015909787602788.Moharregh-Khiabani D, Linker R, Gold R, Stangel M. Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis. Current Neuropharmacology, 2009, 7(1): 60-64. doi:10.2174/157015909787602788.Sormani MP, Rio J, Tintore M, Signori A, Li D, Cornelisse P. Scoring treatment response in patients with relapsing multiplesclerosis. Mult Scler, 2013, 19: 605-612. doi:10.1177/1352458512460605.Sormani MP, Rio J, Tintore M, Signori A, Li D, Cornelisse P. Scoring treatment response in patients with relapsing multiplesclerosis. Mult Scler, 2013, 19: 605-612. doi:10.1177/1352458512460605.Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J NeurolSci, 2013, 40: 307-323. doi: 10.1017/S0317167100014244.Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J NeurolSci, 2013, 40: 307-323. doi: 10.1017/S0317167100014244.Критерии неэффективности терапии и отмены ПИТРС первой линии и замены на препараты второй линии. Журнал неврологии и психиатрии им. С.С. Корсакова, Приложение, 2015, 115(8): 44-44. doi: 10.17116/jnevro20151158244.Criteria for ineffectiveness of therapy and cancellation of multiple sclerosis disease modifying drugs of the first line and replacement them for second-line therapy. Zhurnal Nevrologii i Psikhiatrii Im. S.S. Korsakova. Prilozheniye, 2015, 115 (8): 44-44. doi: 10.17116/jnevro20151158244.Inc. M. Longer-term follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE. Onlinelibraryectrims-congresseu. 2016. Available at: http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/115560/. Accessed April 24, 2016.Inc. M. Longer-term follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE. Onlinelibraryectrims-congresseu. 2016. Available at: http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/115560/. Accessed April 24, 2016.Viglietta V, Miller D, Bar-Or A et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of Clinical and Translational Neurology, 2014, 2(2): 103118. doi:10.1002/acn3.148.Viglietta V, Miller D, Bar-Or A et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of Clinical and Translational Neurology, 2014, 2(2): 103118. doi:10.1002/acn3.148.

The authors declare that there are no conflicts of interest present.